• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma

by | Nov 11, 2024 | Uncategorized

Source: CureToday articles If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses. Read More

KRd56 Versus KRd27 Shows Similar Effectiveness, Safety in R/R Multiple Myeloma

by | Nov 7, 2024 | Uncategorized

Source: CureToday articles In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Read More

Carvykti Effective for R/R Multiple Myeloma in Real-World Setting

by | Nov 5, 2024 | Uncategorized

Source: CureToday articles The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial. Read More

BRCA variants increase risk for multiple myeloma, particularly at younger age

by | Nov 4, 2024 | Uncategorized

Inherited variants in DNA repair genes such as BRCA1 and BRCA2 may increase risk for multiple myeloma, according to results of a retrospective study.Patients with pathogenic germline variants exhibited increased likelihood of having a family or personal history of...

Dexamethasone benefits in multiple myeloma ‘fade into oblivion’ after a couple months

by | Oct 28, 2024 | Uncategorized

Decreasing the amount of dexamethasone that individuals with newly diagnosed multiple myeloma received did not affect survival, according to a secondary analysis of completed clinical trials.Nearly 70% of patients treated with dexamethasone required dose reductions...

Maintenance combination extends PFS in newly diagnosed multiple myeloma

by | Oct 24, 2024 | Uncategorized

The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.The combination reduced risk for disease progression or death by 47% compared with...
« Older Entries
Next Entries »

Recent Content

  • Targeting proteostasis in multiple myeloma through inhibition of LTK
  • IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma
  • EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
  • Patient-reported physical function has ‘real clinical value’ for treating multiple myeloma
  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT